{"id":62246,"date":"2025-11-22T01:06:27","date_gmt":"2025-11-22T00:06:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/transmural-systems-receives-fda-510k-clearance-for-telltale\/"},"modified":"2025-11-22T01:06:27","modified_gmt":"2025-11-22T00:06:27","slug":"transmural-systems-receives-fda-510k-clearance-for-telltale","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/transmural-systems-receives-fda-510k-clearance-for-telltale\/","title":{"rendered":"Transmural Systems Receives FDA 510(k) Clearance for Telltale"},"content":{"rendered":"
\n

ANDOVER, Mass.–(BUSINESS WIRE)–Transmural Systems, a leader in pioneering electrosurgical structural heart therapies, obtained 510(k) clearance from the United States Food and Drug Administration (FDA) for TELLTALE \u2013 the first and only cleared and dedicated electrosurgical guidewire system to prevent coronary obstruction in patients undergoing Transcatheter Aortic Valve Replacement (TAVR) for both<\/b> native aortic stenosis and<\/b> bioprosthetic valve failure<\/b>.<\/p>\n

<\/a>
<\/a><\/p>\n

\nFDA clearance for TELLTALE was granted after a comprehensive pivotal study highlighting the device\u2019s safety and efficacy of leaflet modification in patients at risk for coronary obstruction. TELLTALE, which received Breakthrough Designation, streamlines leaflet modification providing precise, targeted laceration using radiofrequency energy, and delivers predictable outcomes for patients previously considered inoperable where mechanical solutions may fall short.<\/p>\n

\n\u201cAt Transmural Systems, our mission has always been to simplify complex structural heart procedures through innovation,\u201d says Kathleen Pizzuti, Chief Executive Officer of Transmural Systems. \u201cThe FDA\u2019s clearance of TELLTALE reinforces our commitment to delivering a platform of intuitive, high-impact technologies that empower clinicians and improve patient outcomes.\u201d<\/p>\n

\nThe National Institutes of Health (NIH) pioneered the BASILICA procedure to address the problem of coronary obstruction prior to TAVR. The TELLTALE system significantly simplifies BASILICA making it easier for physicians to adopt, ensuring broader accessibility. \u201cWe gratefully acknowledge Dr. Robert J. Lederman, Senior Investigator for Cardiovascular Intervention, and his research team at the National Institutes of Health (NIH) National Heart, Lung, & Blood Institute (NHLBI), and Toby Rogers, MD, of Medstar Washington Hospital Center, Jaffar Khan, MD, of St. Francis Hospital & Health Center, Vasilis Babaliaros, MD, of Emory University Hospital, and Adam Greenbaum, MD, of Emory University Hospital,\u201d says Pizzuti. \u201cTheir contributions have been instrumental in advancing TELLTALE and achieving this significant milestone.\u201d<\/p>\n

\nABOUT TRANSMURAL SYSTEMS<\/b>: Transmural Systems aims to redefine care for structural heart failure by creating innovative solutions that make complex procedures safer and more reproducible. Founded in 2014, their technologies are designed to address high-risk cardiovascular interventions, particularly where conventional devices don\u2019t meet the needs of patients.<\/p>\n

Contacts<\/b> <\/p>\n

\nKoosha Rafiee | V.P. Structural Heart Therapies
\n
(832) 360-6070 | koosha.rafiee@transmuralsystems.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ANDOVER, Mass.–(BUSINESS WIRE)–Transmural Systems, a leader in pioneering electrosurgical structural heart therapies, obtained 510(k) clearance from the United States Food and Drug Administration (FDA) for TELLTALE \u2013 the first and only cleared and dedicated electrosurgical guidewire system to prevent coronary obstruction in patients undergoing Transcatheter Aortic Valve Replacement (TAVR) for both native aortic stenosis and … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62246","6":"format-standard","7":"category-industry"},"yoast_head":"\nTransmural Systems Receives FDA 510(k) Clearance for Telltale - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/transmural-systems-receives-fda-510k-clearance-for-telltale\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Transmural Systems Receives FDA 510(k) Clearance for Telltale - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ANDOVER, Mass.–(BUSINESS WIRE)–Transmural Systems, a leader in pioneering electrosurgical structural heart therapies, obtained 510(k) clearance from the United States Food and Drug Administration (FDA) for TELLTALE \u2013 the first and only cleared and dedicated electrosurgical guidewire system to prevent coronary obstruction in patients undergoing Transcatheter Aortic Valve Replacement (TAVR) for both native aortic stenosis and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/transmural-systems-receives-fda-510k-clearance-for-telltale\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-22T00:06:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251121990490\/en\/2652038\/22\/TMS_Logo_1.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transmural-systems-receives-fda-510k-clearance-for-telltale\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transmural-systems-receives-fda-510k-clearance-for-telltale\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Transmural Systems Receives FDA 510(k) Clearance for Telltale\",\"datePublished\":\"2025-11-22T00:06:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transmural-systems-receives-fda-510k-clearance-for-telltale\\\/\"},\"wordCount\":350,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transmural-systems-receives-fda-510k-clearance-for-telltale\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251121990490\\\/en\\\/2652038\\\/22\\\/TMS_Logo_1.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transmural-systems-receives-fda-510k-clearance-for-telltale\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transmural-systems-receives-fda-510k-clearance-for-telltale\\\/\",\"name\":\"Transmural Systems Receives FDA 510(k) Clearance for Telltale - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transmural-systems-receives-fda-510k-clearance-for-telltale\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transmural-systems-receives-fda-510k-clearance-for-telltale\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251121990490\\\/en\\\/2652038\\\/22\\\/TMS_Logo_1.jpg\",\"datePublished\":\"2025-11-22T00:06:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transmural-systems-receives-fda-510k-clearance-for-telltale\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transmural-systems-receives-fda-510k-clearance-for-telltale\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transmural-systems-receives-fda-510k-clearance-for-telltale\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251121990490\\\/en\\\/2652038\\\/22\\\/TMS_Logo_1.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251121990490\\\/en\\\/2652038\\\/22\\\/TMS_Logo_1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transmural-systems-receives-fda-510k-clearance-for-telltale\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Transmural Systems Receives FDA 510(k) Clearance for Telltale\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Transmural Systems Receives FDA 510(k) Clearance for Telltale - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/transmural-systems-receives-fda-510k-clearance-for-telltale\/","og_locale":"en_US","og_type":"article","og_title":"Transmural Systems Receives FDA 510(k) Clearance for Telltale - Pharma Trend","og_description":"ANDOVER, Mass.–(BUSINESS WIRE)–Transmural Systems, a leader in pioneering electrosurgical structural heart therapies, obtained 510(k) clearance from the United States Food and Drug Administration (FDA) for TELLTALE \u2013 the first and only cleared and dedicated electrosurgical guidewire system to prevent coronary obstruction in patients undergoing Transcatheter Aortic Valve Replacement (TAVR) for both native aortic stenosis and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/transmural-systems-receives-fda-510k-clearance-for-telltale\/","og_site_name":"Pharma Trend","article_published_time":"2025-11-22T00:06:27+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251121990490\/en\/2652038\/22\/TMS_Logo_1.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/transmural-systems-receives-fda-510k-clearance-for-telltale\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/transmural-systems-receives-fda-510k-clearance-for-telltale\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Transmural Systems Receives FDA 510(k) Clearance for Telltale","datePublished":"2025-11-22T00:06:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/transmural-systems-receives-fda-510k-clearance-for-telltale\/"},"wordCount":350,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/transmural-systems-receives-fda-510k-clearance-for-telltale\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251121990490\/en\/2652038\/22\/TMS_Logo_1.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/transmural-systems-receives-fda-510k-clearance-for-telltale\/","url":"https:\/\/pharma-trend.com\/en\/transmural-systems-receives-fda-510k-clearance-for-telltale\/","name":"Transmural Systems Receives FDA 510(k) Clearance for Telltale - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/transmural-systems-receives-fda-510k-clearance-for-telltale\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/transmural-systems-receives-fda-510k-clearance-for-telltale\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251121990490\/en\/2652038\/22\/TMS_Logo_1.jpg","datePublished":"2025-11-22T00:06:27+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/transmural-systems-receives-fda-510k-clearance-for-telltale\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/transmural-systems-receives-fda-510k-clearance-for-telltale\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/transmural-systems-receives-fda-510k-clearance-for-telltale\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251121990490\/en\/2652038\/22\/TMS_Logo_1.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251121990490\/en\/2652038\/22\/TMS_Logo_1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/transmural-systems-receives-fda-510k-clearance-for-telltale\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Transmural Systems Receives FDA 510(k) Clearance for Telltale"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62246","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62246"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62246\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62246"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62246"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62246"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}